SELECTED READING
- Borish LC et al. Interleukin-4 receptor in moderate atopic asthma: A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 160:1816, 1999
- Bryan SA et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2149, 2000
- Busse WW, McGill KA, Horwitz RJ. Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 29(Suppl 2): 110, 1999
- Byrd RP Jr, Krishnaswamy G, Roy TM. Difficult-to-manage asthma: How to pinpoint the exacerbating factors. Postgrad Med 108(6):37, 2000
- Galant SP et al. Diskus and diskhaler: Efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 82:273,1999
- Kon OM et al. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352:1109,1998
- Krishnaswamy G et al. Molecular therapies for asthma. Fed Practitioner 2:16, 1999
- Leckie MJ et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response, Lancet 356:2144, 2000
- Metzger WJ, Nyce JW. Oligonucleotide therapy of allergic asthma. J Allergy Clin Immunol 104(2 Pt 1):260,1999
- Milgrom H et al. Treatment of allergic asthma with monoclonal anti-lgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341:1966, 1999
- Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 320:1368, 2000
- Wong WS, Koh DS. Advances in immunopharmacology of asthma. Biochem Pharmacol 59:1323, 2000